Advanced

A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide

Alghazali, Mohammed LU ; Löfgren, Annica LU ; Jørgensen, Leif ; Svensson, Maja ; Fagerlund, Karin and Bjartell, Anders LU (2019) In Scandinavian Journal of Urology
Abstract

Objective: This retrospective, single-centre, non-interventional, registry-based study evaluated patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in daily clinical practice at Skåne University Hospital, Malmö, Sweden. Materials and methods: Registry data were reviewed for patients treated with enzalutamide pre- or post-chemotherapy initiated between December 2013 and June 2017. The primary endpoint was overall survival (OS) in post-chemotherapy patients. Secondary endpoints were enzalutamide treatment duration in the pre- and post-chemotherapy setting. This study was approved by the Lund regional Ethics Review Board (Dnr:2017/716) and is registered with ClinicalTrials.gov (NCT03328364).... (More)

Objective: This retrospective, single-centre, non-interventional, registry-based study evaluated patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in daily clinical practice at Skåne University Hospital, Malmö, Sweden. Materials and methods: Registry data were reviewed for patients treated with enzalutamide pre- or post-chemotherapy initiated between December 2013 and June 2017. The primary endpoint was overall survival (OS) in post-chemotherapy patients. Secondary endpoints were enzalutamide treatment duration in the pre- and post-chemotherapy setting. This study was approved by the Lund regional Ethics Review Board (Dnr:2017/716) and is registered with ClinicalTrials.gov (NCT03328364). Results: A total of 102 pre-chemotherapy and 98 post-chemotherapy patients were included. Median age was higher in the pre- than in the post-chemotherapy group (77 vs 72 years, respectively). Median OS in post-chemotherapy patients from initiation of enzalutamide until death from any cause was 14.3 months [95% confidence interval (CI) = 11.00–18.20]. Median treatment duration was 13.8 months (95% CI = 11.4–20.2) and 7.6 months (95% CI = 6.3–10.2) for pre- and post-chemotherapy patients, respectively. Conclusion: Enzalutamide can be used to effectively treat mCRPC patients in daily clinical settings, despite the patients being older and less healthy than those enrolled in the previous randomised, clinical registration studies.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Enzalutamide, metastatic castration-resistant prostate cancer, registries
in
Scandinavian Journal of Urology
publisher
Taylor & Francis
external identifiers
  • scopus:85071972443
  • pmid:31815592
ISSN
2168-1805
DOI
10.1080/21681805.2019.1657494
language
English
LU publication?
no
id
108068ae-6368-43d5-a37c-23b39b1ba172
date added to LUP
2019-09-18 15:10:16
date last changed
2020-10-27 01:26:48
@article{108068ae-6368-43d5-a37c-23b39b1ba172,
  abstract     = {<p>Objective: This retrospective, single-centre, non-interventional, registry-based study evaluated patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in daily clinical practice at Skåne University Hospital, Malmö, Sweden. Materials and methods: Registry data were reviewed for patients treated with enzalutamide pre- or post-chemotherapy initiated between December 2013 and June 2017. The primary endpoint was overall survival (OS) in post-chemotherapy patients. Secondary endpoints were enzalutamide treatment duration in the pre- and post-chemotherapy setting. This study was approved by the Lund regional Ethics Review Board (Dnr:2017/716) and is registered with ClinicalTrials.gov (NCT03328364). Results: A total of 102 pre-chemotherapy and 98 post-chemotherapy patients were included. Median age was higher in the pre- than in the post-chemotherapy group (77 vs 72 years, respectively). Median OS in post-chemotherapy patients from initiation of enzalutamide until death from any cause was 14.3 months [95% confidence interval (CI) = 11.00–18.20]. Median treatment duration was 13.8 months (95% CI = 11.4–20.2) and 7.6 months (95% CI = 6.3–10.2) for pre- and post-chemotherapy patients, respectively. Conclusion: Enzalutamide can be used to effectively treat mCRPC patients in daily clinical settings, despite the patients being older and less healthy than those enrolled in the previous randomised, clinical registration studies.</p>},
  author       = {Alghazali, Mohammed and Löfgren, Annica and Jørgensen, Leif and Svensson, Maja and Fagerlund, Karin and Bjartell, Anders},
  issn         = {2168-1805},
  language     = {eng},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Urology},
  title        = {A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide},
  url          = {http://dx.doi.org/10.1080/21681805.2019.1657494},
  doi          = {10.1080/21681805.2019.1657494},
  year         = {2019},
}